New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 23, 2013
07:10 EDTATHXAthersys replaces equity facility with Aspire Capital
Athersys announced that it has put in place a new equity facility with Aspire Capital Fund, LLC to replace the prior two-year agreement that has ended. Under the new agreement, Athersys has the right to sell up to $25M in shares of common stock to Aspire Capital under certain conditions over a two-year period. The agreement represents an additional tool for accessing capital to complement business collaborations, grants and traditional fundraising, and as such, provides the Company with added financial strength and flexibility.
News For ATHX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
05:48 EDTATHXStocks with implied volatility movement; CSX ATHX
Stocks with implied volatility movement; CSX (CSX) 40, Athersys (ATHX) 151 according to iVolatility.
April 21, 2015
09:45 EDTATHXMaxim still bullish on Athersys, says data show 'strong signal'
Maxim analyst Jason Kolbert told investors today that he remains bullish on Athersys after the company announced Friday morning its stroke trial missed the primary and secondary endpoints. Kolbert says the data show MultiStem appears to be able to extend the treatment window in stroke from a few hours to 36 hours, which he calls "dramatic." He views the data as showing a "strong signal," and added "it seems that no one wants to hear or look" at it. The analyst expects Athersys to announce plans to move forward in a Phase IIb/III global trial in the U.S., Europe and Japan. He pointed out that Maxim hopes to announce next week a series of conference calls with Athersys management and experts. Kolbert kept a Buy rating on Athersys with a $9 price target. The stock is trading down 3c to $1.32 in early trading.
April 20, 2015
11:53 EDTATHXPiper Jaffray biotech analysts hold an analyst/industry conference call
Biotech Analysts Tenthoff and Adler, along with Dr. Stanley Tuhrim, discuss Athersys' MultiStem ischemic stroke results on an Analyst/Industry conference call to be held on April 20 at 1 pm.
April 17, 2015
12:21 EDTATHXOn The Fly: Top stock stories at midday
Subscribe for More Information
11:04 EDTATHXAthersys data provide 'glimmer of activity,' says Piper Jaffray
Subscribe for More Information
10:07 EDTATHXHigh option volume stocks
Subscribe for More Information
09:14 EDTATHXOn The Fly: Pre-market Movers
Subscribe for More Information
06:27 EDTATHXAthersys says MultiStem missed primary, secondary endpoints
Subscribe for More Information
05:56 EDTATHXStocks with implied volatility above IV index mean; ATHX GMCR
Stocks with implied volatility above IV index mean; Athersys (ATHX) 415, Keurig Green Mountain (GMCR) 52 according to iVolatility.
April 16, 2015
11:09 EDTATHXAthersys upcoming data could take shares to 45c, says Piper Jaffray
Subscribe for More Information
07:16 EDTATHXAthersys volatility elevated into Phase 2 ischemic stroke trial results
Athersys April call option implied volatility is at 408, May is at 390, July is at 230, October is at 204; compared to its 26-week average of 161 according to Track Data, suggesting large price movement into Phase 2 ischemic stroke trial results to be presented at ESOC.
05:59 EDTATHXStocks with implied volatility above IV index mean; ATHX GMCR
Stocks with implied volatility above IV index mean; Athersys (ATHX) 390, Keurig Green Mountain (GMCR) 53 according to iVolatility.
April 15, 2015
06:07 EDTATHXStocks with implied volatility above IV index mean; ATHX WETF
Subscribe for More Information
April 13, 2015
07:38 EDTATHXAthersys volatility elevated into Phase 2 ischemic stroke trial results
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use